369638-68-6

Basic information

• Product Name: Carbamic acid, (5-methylpyrazinyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (5-methylpyrazinyl)-, 1,1-dimethylethyl ester (9CI);N-Boc-2-amino-5-methylpyrazine;2-Boc-Amino-5-methylpyrazine;tert-butyl N-(5-Methylpyrazin-2-yl)carbaMate;CarbaMic acid,N-(5-Methyl-2-pyrazinyl)-, 1,1-diMethylethyl ester;2-N-Boc-aMino-5-Methylpyrazin;1,1-diMethylethyl ester (9CI)
• CAS NO: 369638-68-6
• Molecular Formula: C₁₀H₁₅N₃O₂
• Molecular Weight: 209.245
• EINECS: 200-589-5
• Product Categories: N-BOC
• Mol File: 369638-68-6.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 268.763 °C at 760 mmHg
• Flash Point: 116.344 °C
• Appearance: /
• Density: 1.155 g/cm³
• Vapor Pressure: 0.008mmHg at 25°C
• Refractive Index: 1.543
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 11.63±0.70(Predicted)
• CAS DataBase Reference: Carbamic acid, (5-methylpyrazinyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (5-methylpyrazinyl)-, 1,1-dimethylethyl ester (9CI)(369638-68-6)
• EPA Substance Registry System: Carbamic acid, (5-methylpyrazinyl)-, 1,1-dimethylethyl ester (9CI)(369638-68-6)

Safety Data

• Hazardous Substances Data: 369638-68-6(Hazardous Substances Data)

Usage

General Description

Carbamic acid, (5-methylpyrazinyl)-, 1,1-dimethylethyl ester (9CI) is a chemical compound that can also be classified as an ester derivative of carbamic acid. It contains the 5-methylpyrazinyl functional group and the 1,1-dimethylethyl ester group, leading to its complex chemical structure. Carbamic acid, (5-methylpyrazinyl)-, 1,1-dimethylethyl ester (9CI) is generally categorized under the 9th Collective Index (9CI) of chemicals, a systematic listing of organic compounds. The specific properties, uses, and potential hazards of this chemical will depend on its exact structural configuration and the surrounding conditions. Please consult with a chemist or a material science expert to understand more about its specific characteristics, applications, and safety protocols.

InChI:InChI=1/C10H15N3O2/c1-7-5-12-8(6-11-7)13-9(14)15-10(2,3)4/h5-6H,1-4H3,(H,12,13,14)

Upstream product

• 5521-55-1 2-methylpyrazin-5-carboxylic acid 
• 75-65-0 tert-butyl alcohol 
• 4129-17-3 diphenylphosphoranyl azide 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 

Downstream Products

• 369638-69-7 tert-butyl (5-(bromomethyl)pyrazin-2-yl)carbamate 
• 5521-58-4 5-methylpyrazin-2-amine 
• 1380645-97-5 3-(4-Fluoro-phenyl)-2-(4-methanesulfonyl-phenyl)-N-(5-methoxymethyl-pyrazin-2-yl)-propionamide 
• 1380646-32-1 (S)-3-(4-Fluoro-phenyl)-N-(5-hydroxymethyl-pyrazin-2-yl)-2-(4-methanesulfonyl-phenyl)-propionamide 
• 1380646-31-0 (R)-3-(4-Fluoro-phenyl)-N-(5-hydroxymethyl-pyrazin-2-yl)-2-(4-methanesulfonyl-phenyl)-propionamide 
• 710322-47-7 tert-butyl 5-(cyanomethyl)pyrazin-2-ylcarbamate 
• 1315380-71-2 tert-butyl 5-((5-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamido)-2-methylphenylamino)methyl)pyrazin-2-ylcarbamate 
• 369638-71-1 (5-aminomethyl-pyrazin-2-yl)-carbamic acid tert-butyl ester 

Relevant articles and documents

Aminoheteroaryl benzamides as kinase inhibitors

The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS

The present application relates to nitrogen-containing fused ring compounds shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof as CRTH2 antagonist, wherein X1, X2, X3, X4, X5, W, X, Y, L1, L2, L3, A, B are as defined in the description; the present application further relates to a method for preparing the compounds, a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, a use of the compounds for the manufacture of a medicament for the treatment and/or prevention of diseases related to activity of CRTH2.

TYPE II RAF KINASE INHIBITORS

The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.